Full Breakdown
Merck's Strategic Acquisition of Terns Pharmaceuticals: A $6 Billion Bet on Oncology
3/25/2026, 2:13:31 PM
Merck's Acquisition Plans
Merck & Co. is reportedly nearing a $6 billion all-cash acquisition of Terns Pharmaceuticals Inc., a biotech firm specializing in treatments for chronic myeloid leukemia (CML). This potential deal, which could be finalized within days, is part of Merck's strategy to bolster its oncology pipeline ahead of the impending patent expiration of its blockbuster cancer drug, Keytruda, in 2028. Terns, based in Foster City, California, has seen its stock rise significantly, reflecting investor optimism about its lead asset, TERN-701, an investigational drug showing promising early clinical results.
Background on Terns Pharmaceuticals
Terns Pharmaceuticals has gained attention for its innovative approach to treating CML, a rare cancer affecting blood and bone marrow. The company’s lead candidate, TERN-701, has demonstrated a major molecular response in 64% of heavily pretreated patients within 24 weeks, a figure described as "unprecedented." This promising data was highlighted at the American Society of Hematology annual meeting, positioning Terns as a key player in the oncology space.
Merck's Strategic Context
Merck's move to acquire Terns aligns with its broader strategy to mitigate potential revenue losses from Keytruda, which generated over $30 billion in sales in 2025. The company has already engaged in significant acquisitions, including Verona Pharma for $10 billion and Cidara Therapeutics for $9.2 billion, as part of its aggressive portfolio-building efforts. The acquisition of Terns would further enhance Merck's oncology offerings and potentially allow it to capture market share from existing therapies like Novartis' Scemblix.
Financial Implications and Market Reactions
The acquisition is expected to value Terns at a premium to its market capitalization of approximately $5.3 billion. Following the news of the potential deal, Terns' shares rose significantly, reflecting investor confidence in the company's future prospects. However, some institutional investors have expressed caution, citing that much of the potential upside may already be priced into Terns' stock, which has surged 1,300% over the past year.
Criticism and Concerns
Despite the strategic rationale, there are concerns regarding the high valuation of Terns and the inherent risks associated with clinical-stage assets. Critics argue that Merck must carefully evaluate whether the potential benefits of acquiring Terns justify the premium required, especially given the competitive landscape in oncology. The recent decision by Merck to withdraw from a $30 billion acquisition of Revolution Medicines underscores the company's disciplined approach to capital allocation.
What's Next for Merck and Terns
The immediate focus will be on the finalization of the acquisition deal, which hinges on regulatory and shareholder approvals. Investors are also keenly awaiting updates from the CARDINAL trial, which will provide critical data on TERN-701's efficacy and safety. Positive results could solidify the rationale for the acquisition, while negative findings may jeopardize the deal.
Conclusion
Merck's potential acquisition of Terns Pharmaceuticals represents a significant strategic move to enhance its oncology pipeline in anticipation of Keytruda's patent expiration. While the deal could accelerate Merck's growth in cancer therapies, it also carries substantial risks that the company must navigate carefully. The coming months will be pivotal as both companies approach critical clinical milestones and finalize negotiations.
